Format

Send to:

Choose Destination
See comment in PubMed Commons below
BMC Neurol. 2011 Sep 23;11:113. doi: 10.1186/1471-2377-11-113.

What is the potential of oligodendrocyte progenitor cells to successfully treat human spinal cord injury?

Author information

  • 1Green Templeton College, Woodstock Road, Oxford, OX2 6HG, UK. robert.watson@gtc.ox.ac.uk

Abstract

BACKGROUND:

Spinal cord injury is a serious and debilitating condition, affecting millions of people worldwide. Long seen as a permanent injury, recent advances in stem cell research have brought closer the possibility of repairing the spinal cord. One such approach involves injecting oligodendrocyte progenitor cells, derived from human embryonic stem cells, into the injured spinal cord in the hope that they will initiate repair. A phase I clinical trial of this therapy was started in mid 2010 and is currently underway.

DISCUSSION:

The theory underlying this approach is that these myelinating progenitors will phenotypically replace myelin lost during injury whilst helping to promote a repair environment in the lesion. However, the importance of demyelination in the pathogenesis of human spinal cord injury is a contentious issue and a body of literature suggests that it is only a minor factor in the overall injury process.

SUMMARY:

This review examines the validity of the theory underpinning the on-going clinical trial as well as analysing published data from animal models and finally discussing issues surrounding safety and purity in order to assess the potential of this approach to successfully treat acute human spinal cord injury.

PMID:
21943254
[PubMed - indexed for MEDLINE]
PMCID:
PMC3189870
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk